The specific features of the course of acute vulvovaginal candidiasis and its therapy with fenticonazole in reproductive-aged women with different phenotypes of polycystic ovary syndrome


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To establish the specific features of the course acute vulvovaginal candidiasis (VVC) and therapy with fenticonazole in reproductive-aged women with different phenotypes of polycystic ovary syndrome (PCOS). Subjects and methods. The investigation enrolled 65 women of reproductive age (mean age, 27.4+3.6 years) with severe acute VVC. A study group included 35 women with PCOS (Group 1); a comparison group consisted of 30 women without PCOS (Group 2). To treat acute VVC, all the women received an intravaginal 600-mg fenticonazole capsule once overnight on days 1 and 4 of treatment. In both groups, the efficiency of treatment for acute VVC was evaluated at 10-14 days, 1 and 3 months after therapy. Results. At 10-14 days and 1 month after fenticonazole treatment, its efficiency was high in both groups and amounted to 94.3 and 96.7% (at 10-14 days after treatment) and 91.4% and 93.3% (at 1 month after treatment), respectively. At 3 months after treatment, its efficiency remained high in the comparison (non-PCOS) group and amounted to 90%, whereas that in the study (PCOS) group significantly decreased to 71.4% (p <0.05). In the women with PCOS, the recurrence rate of VVC depended directly proportionally (r = 0.60; p <0.001) on the presence of carbohydrate metabolic disturbances as glucose intolerance and insulin resistance (r = 0.50; p <0.01) and overweight or obesity (r = 0.77 p <0.001). Almost all women with an exacerbation of VVC were diagnosed with glucose intolerance or insulin resistance (Homeostasis model assessment of insulin resistance (HOMA-IR) was more than 2.5 scores). In women with hyperandrogenism (phenotypes A, B, C), an exacerbation of VVC occurred significantly more frequently (r = 0.40 p <0.01), Conclusion. Recurrent VVC in women with PCOS may be prevented by correcting main metabolic changes, overcoming insulin resistance, and restoring the ovulatory cycle. In case of an exacerbation of VVC in this patient group, it is recommended to use fenticonazole at a dose of600 mg twice with an interval of 3 days. Thus, fenticonazole may be recommended as the first-choice drug in treating acute VVC in reproductive-aged women.

Full Text

Restricted Access

About the authors

E. I Abashova

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: abashova@yandex.ru

M. I Yarmolinskaya

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: m.yarmolinskaya@gmai.com

E. V Misharina

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: mishellena@gmail.com

References

  1. Yano J, Sobel J.D., Nyirjesy P., et al. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health. 2019; 19(1): 48. doi: 10.1186/s12905-019-0748-8
  2. Denning D.W., Kneale M., Sobel J.D., Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018; 18(11): e339-e47. doi: 10.1016/S1473-3099(18)30103-8
  3. Sobel J.D. Recurrent vulvovaginal candidiasis. Am J. Obstet Gynecol. 2016; 214: 15-21. doi: 10.1016/j.ajog.2015.06.067
  4. Blostein F., Levin-Sparenberg E., Wagner J., Foxman B. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017; 27: 575-582. doi: 10.1016/j. annepidem.2017.08.010
  5. Foxman B., Muraglia R., Dietz J.P., et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J. Low Genit Tract Dis. 2013; 17: 340-5. 10.1097/ LGT.0b013e318273e8cf
  6. Ilkit M., Guzel A.B. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective. Crit Rev Microbiol 2011; 37:250-61. 10.3109/1040841X.2011.576332
  7. Домейка М., Савичева А., Соколовский Е., Баллард Р., Унемо М., ред. Руководство по лабораторной диагностике инфекций урогенитального тракта. СПб.: Н-Л, 2012; 287 с.
  8. Савичева А.М., Шипицына Е.В. Рецидивирующий урогенитальный кандидоз: особенности диагностики и лечения. Медицинский совет. 2015; (9): 15-17. [Savicheva A.M., Shipitsyna E.V. Recurrent urogenital candidiasis: diagnosis and treatment. Medical Council. 2015; (9): 15-17. (In Russ.)]. https:// doi.org/10.21518/2079-701X-2015-9-15-17
  9. Workowski K.A., Bolan G.A.; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in MMWR Recomm Rep. 2015 Aug 28;64(33):924]. MMWR Recomm Rep. 2015;64(RR-03):1-137.
  10. Клинические рекомендации по диагностике и лечению заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. М.: Российское общество акушеров-гинекологов; 2019. 56 с.
  11. Hong E., Dixit S., Fidel P. L., Bradford J., Fischer G. Vulvovaginal candidiasis as a chronic disease: diagnostic criteria and definition. J. Low Genit Tract Dis. 2014; 18: 31-38. doi: 10.1097/ LGT.0b013e318287ace.
  12. Fox E.P., Nobile C.J. A sticky situation: untangling the transcriptional network controlling biofilm development in Candida albicans.Transcription. 2012; 3: 315-322. doi: 10.4161/trns.22281
  13. Nett J.E., Zarnowski R., Cabezas-Olcoz J., et al. Host contributions to construction of three device-associated Candida biofilms. Infect Immun. 2015; 83(12): 4630-8. doi: 10.1128/IAI.00931-15
  14. Nobile C.J., Johnson A.D. Candida albicans biofilms and human disease. Ann Rev Microbiol. 2015; 69: 71-92. doi: 10.1146/annurev-micro-091014-104330
  15. Байрамова Г.Р., Баранов И.И., Припутневич Т.В., Чернова В.Ф. Вульвовагинальный кандидоз: клинические и терапевтические аспекты в практике акушера-гинеколога. Акушерство и гинекология: Новости. Мнения. Обучения. 2017; 18(4): 63-69. doi: 10.24411/2303-9698-2017-00009
  16. Teede H.J., Misso M.L., Costello M.F., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome [published correction appears in Hum Reprod. 2019; 34(2): 388]. Hum Reprod. 2018; 33(9): 1602-18. doi: 10.1093/humrep/dey256
  17. Moran L.J., Misso M.L., Wild R.A., Norman R.J. Impaired glucose tolerance, type II diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010; 16: 347-363. doi: 10.1093/humupd/dmq001
  18. Rubin K.H., et al. Development and risk factors of type 2 diabetes in a Nationwide population of women with polycystic ovary syndrome. J. Clin Endocr Metabolism. 2017; 102: 3848-57. doi: 10.1210/jc.2017-01354
  19. Azziz R., Carmina E., Chen Z., et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2: 16057. doi: 10.1038/nrdp.2016.57
  20. NIH Evidence based workshop panel, NIH Evidence based workshop on Polycystic Ovary Syndrome. http://prevention.nih.gov/workshops/2012/pcos/ resources.aspx., 2012.
  21. Sherrard J., Wilson J., Donders G., et al. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J. STD AIDS. 2018; 29(13): 1258-72. doi: 10.1177/0956462418785451.
  22. Tumietto F., Giacomelli L. Fenticonazole: an effective topical treatment for superficial mycoses as the first-step of antifungal stewardship program. Eur Rev Med Pharmacol Sci. 2017; 21(11): 2749-56.
  23. Veraldi S., Milani R. Topical fenticonazole in dermatology and gynaecology. Drugs. 2008; 68(15): 2183-94. doi: 10.2165/00003495-200868150-00007
  24. Panthagani A.P., Tidman M.J. Diagnosis directs treatment in fungal infections of the skin. Practitioner. 2015; 259(1786): 25-9, 3. PMID: 26738249
  25. Kovachev S.M.,Vatcheva-Dobrevska R.S. Local probiotic therapy for vaginal candida albicans infections Probiotics & Antimicro. Prot. 2015; 7(1): 38-44. https://doi.org/10.1007/s12602-014-9176-0.
  26. De Bernardis F., Cassone A. [Comparison of the effects of fenticonazole and econazole on the aspartic proteinase secreted by Candida albicans. J. Contracept Fertil Sex. 1996; 24: 163-165. (in French)]. PMID: 8611939
  27. Antonopoulou S., Aoun M., Alexopoulos E.C., Baka S., Logothetis E., Kalambokas T., Zannos A., Papadias K., Grigoriou O., Kouskouni E., Velegraki A. Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on t he prevalent genotypes. Antimicrob Agents Chemother. 2009; 53(5): 2181-4. doi: 10.1128/AAC.01413-08
  28. Малова И.О., Афанасьева И.Г. Острый вульвовагинальный кандидоз: новые возможности. Бюллетень медицинской науки. 2017; 3 (7): 60-64.
  29. Абакарова П.Р., Прилепская В.Н., Межевитинова Е.А., Байрамова Г.Р., Иванова Е.В. Современные возможности эффективного лечения вульвовагинального кандидоза. Акушерство и гинекология. 2012; 7: 79-82.
  30. Логутова Л.С., Зароченцева Н.В., Дуб Н.В., Меньшикова Н.С. Опыт применения Ломексина в лечении больных с острым вульвовагинальным кандидозом. Российский вестник акушера-гинеколога. 2012; 4: 76-80.
  31. Мирзабалаева А.К., Жорж О.Н. Гормональные нарушения при гинекологических заболеваниях - фактор риска хронического рецидивирующего течения кандидоза гениталий. Проблемы медицинской микологии. 2012. 14(2): 25-29.
  32. Cassar S., Misso M.L., Hopkins W.G., et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016; 31: 2619-31. doi: 10.1093/humrep/dew243
  33. Радзинский В.Е., Артымук Н.В., Берлев И.В., Волков В.Г., Евтушенко И.Д., Кар ахали с Л.Ю., Ку карская И. И., Сафронова М. М., Зуева Г. П., Петрова М.С. Рандомизированное многоцентровое исследование эффективности применения 600 и 1200 мг препарата Ломексин в лече-нии кандидозного вульвовагинита у женщин репродуктивного возраста. Акушерство и гинекология. 2013; 2: 113-18
  34. Sanguinetti M., Cantón E., Torelli R., Tumietto F., Espinel-Ingroff A., Posteraro B. In vitro Activity of Fenticonazole against Candida and Bacterial Vaginitis Isolates Determined by Mono- or Dual-Species Testing Assays. Antimicrobial Agents and Chemotherapy. 2019; 63(7): e02693-18. doi: 10.1128/AAC.02693-18

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies